No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 24.2x · 10Y median 15.1x · 76th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 16
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:37:45.313Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Mangoceuticals, Inc. (MGRX) stock was $0.45 as of Oct 6, 2026, 4:00 PM EDT, up 7.66% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -81.4% · 3-year avg -64.6%/yr
Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men.
Medical - Healthcare Information Services · Dallas, TX
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.09
vs Estimate
N/A
Revenue
$68757.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1MGRX | $7.64M | $0.45 | +7.66% | -81.44% | N/A | N/A | N/A |
| 2NDRA | $7.67M | $6.04 | -4.28% | +9.71% | -83.91% | N/A | vs MGRX |
| 3CNSP | $7.75M | $5.30 | +0.03% | -40.68% | -91.63% | N/A | vs MGRX |
| 4QNCX | $7.46M | $26.81 | -4.59% | -91.38% | -72.96% | N/A | vs MGRX |
| 5APRE | $7.87M | $0.64 | -5.94% | -54.79% | -63.30% | N/A | vs MGRX |
| 6TRAW | $7.92M | $0.52 | -2.99% | -75.96% | -64.14% | -64.35% | vs MGRX |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.45
High
N/A
